Cellectis (CLLS) EBT Margin Growth (5y) (2020 - 2026)
Powered by 
Analysis
Cellectis (CLLS) EBT Margin Growth (5y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,376.00 |
| Mar 31, 2026 | -11,368.00 |
| Dec 31, 2025 | -31,784.00 |
| Sep 30, 2025 | 53,877.00 |
| Jun 30, 2025 | 123,260.00 |
| Mar 31, 2025 | -655.00 |
| Dec 31, 2024 | 56,917.00 |
| Sep 30, 2024 | 33,206.00 |
| Jun 30, 2024 | 273,279.00 |
| Mar 31, 2024 | 248,890.00 |
| Dec 31, 2023 | -3.87 Mn |
| Sep 30, 2023 | 276,964.00 |
| Jun 30, 2023 | 309,038.00 |
| Mar 31, 2023 | -1.53 Mn |
| Dec 31, 2022 | 46,722.00 |
| Sep 30, 2022 | -1.29 Mn |
| Jun 30, 2022 | -114,918.00 |
| Mar 31, 2022 | -4,423.00 |
| Dec 31, 2021 | 17,928.00 |
| Sep 30, 2021 | -39,524.00 |